Photo by nci from unsplash
The recommended phase 2 dose (RP2D) of anticancer agents is determined traditionally by dose‐limiting toxicities. Nontoxicity or biological endpoints such as pharmacokinetics, pharmacodynamics, and efficacy can also be used to… Click to show full abstract
The recommended phase 2 dose (RP2D) of anticancer agents is determined traditionally by dose‐limiting toxicities. Nontoxicity or biological endpoints such as pharmacokinetics, pharmacodynamics, and efficacy can also be used to identify RP2D, which may be relevant to molecularly targeted agents (MTAs).
Keywords:
targeted agents;
phase dose;
determinants recommended;
recommended phase
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!